Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Equal-Weight and raises the price target from $116 to $140.
Morgan Stanley Maintains Equal-Weight on Ascendis Pharma, Raises Price Target to $140
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.